Methaemoglobinaemia

Meet the patient

A 62-year-old man turns slate-grey ten minutes after a benzocaine throat spray for upper gastrointestinal endoscopy. He is breathless and confused. The nurse puts him on 100 percent oxygen and his saturation, stuck at 84 percent, does not move. The arterial blood gas shows a PaO2 of 90 mmHg and a calculated saturation of 98 percent.[1][3]

The monitor looks reassuring and lies. This is methaemoglobinaemia until co-oximetry proves otherwise. Two questions run the resus bay: why is the cyanosis not responding to oxygen? and is it safe to give methylene blue? Everything below answers them — and the second question turns on a single enzyme assay, G6PD, because in its absence the antidote causes haemolysis.[1][4]

The signature triad — and the monitor that lies

Methaemoglobinaemia tests three habits at once: your reflex to trust the monitor, your grasp of one elegant antidote, and your awareness of the one contraindication that turns the antidote into a poison. The pathology is deceptively simple — the haem iron is oxidised from ferrous Fe2+ to ferric Fe3+, and ferric iron cannot bind oxygen. Worse, by stabilising the relaxed conformation of the neighbouring subunits it shifts the oxygen-haemoglobin dissociation curve to the left, so the oxygen that remains bound is held more tightly and released less readily to the tissues.[2]

A small amount of methaemoglobin forms constantly by spontaneous auto-oxidation, and an efficient red-cell reducing system holds the steady state under 1 percent; disease is defined as a level over 1.5 percent. The bedside syndrome to recognise is sudden cyanosis after a procedure, a drug, or an exposure that does not improve with oxygen, with chocolate-brown blood and a saturation gap — the pulse oximeter near 85 percent while the arterial PaO2 is normal.[1]

Acquired versus congenital — and severity by percentage

Classify on mechanism first, then on severity, because together they set the treatment. Acquired oxidant poisoning is over 99 percent of cases and reverses with methylene blue; congenital disease is rare, lifelong, and largely managed without the antidote.[1]

[1]

The second axis is severity by percentage, and it sets who gets the antidote. Mild disease, under 10 percent, is often asymptomatic and managed by withdrawing the oxidant and giving oxygen. Moderate disease, 10 to 30 percent, brings slate-grey cyanosis, exertional dyspnoea, headache and fatigue, and methylene blue if symptomatic. Severe disease, 30 to 50 percent, adds dyspnoea at rest, syncope, confusion, chest pain and ischaemic ECG changes; over 50 percent brings seizures, coma, lactic acidosis, arrhythmia and shock; over 70 percent is usually lethal. The threshold to treat is symptomatic disease or a level over 30 percent.[1][5]

How common, and who is susceptible

Acquired methaemoglobinaemia is uncommon but under-recognised, because the monitor looks reassuring. The largest modern series — Ash-Bernal, 138 cases over two academic centres in 28 months — identified dapsone and topical or local anaesthetics as the leading drug causes, with a case-fatality around 1 to 3 percent in treated cases that climbs sharply once methaemoglobin exceeds 50 to 60 percent.[4]

[1] [1]

The susceptibility factors are the ones examiners probe. Infants under four to six months have fetal haemoglobin that oxidises readily, gut flora that reduces nitrate to the more potent nitrite, and cytochrome b5 reductase activity only 50 to 60 percent of the adult value — the molecular basis of well-water blue baby syndrome. G6PD deficiency impairs NADPH-dependent reduction and raises the risk of oxidative haemolysis, and it makes methylene blue contraindicated. Anaemia and cardiopulmonary disease lower the reserve for a given percentage, and an anaemic patient may be profoundly hypoxic without cyanosis because the total haemoglobin is too low to reach the 1.5 g/dL absolute threshold.[1][5]

The oxidants — OXIDANTS

The unifying theme is the oxidant, and the sources cluster into one mnemonic. Name the oxidant from the history and you have named the cause.[1]

[1]

The detail worth carrying into the viva: dapsone's N-hydroxylamine metabolite is the oxidant and the drug has a 20 to 40 hour half-life, so methaemoglobin recurs after each methylene-blue dose — co-prescribe cimetidine to block the CYP generation of the metabolite. Benzocaine is the classic iatrogenic cause, abrupt minutes after a topical spray for endoscopy, bronchoscopy, transoesophageal echo or intubation, and the FDA withdrew over-the-counter benzocaine teething products in 2018 after severe infant cases. Phenazopyridine colours the urine orange — a clue. Nitroprusside releases both cyanide and nitrite. Smoke inhalation can combine carbon monoxide, cyanide and methaemoglobinaemia at once.[4][6]

The redox balance — and the methylene-blue hinge

The whole syndrome flows from one number: the steady-state balance between haemoglobin auto-oxidation and the red-cell reducing systems. Two enzymatic routes hold methaemoglobin under 1 percent, and the antidote works through the normally dormant one.[1]

The major pathway — NADH-cytochrome b5 reductase, also called diaphorase I — performs about 95 percent of daily methaemoglobin reduction. NADH from glycolysis reduces cytochrome b5, which reduces ferric methaemoglobin back to functional ferrous haemoglobin. This is the pathway genetically deficient in congenital cytochrome b5 reductase deficiency. The minor pathway — NADPH-methaemoglobin reductase, diaphorase II — uses NADPH from the hexose-monophosphate shunt but is normally dormant because it lacks an endogenous electron carrier.[1]

Methylene blue supplies that missing carrier, and that single fact is the whole of antidote therapy. It is reduced to leukomethylene blue by NADPH-methaemoglobin reductase, and leukomethylene blue non-enzymatically reduces ferric methaemoglobin back to ferrous haemoglobin. This is the molecular basis of methylene-blue therapy — and the reason it is completely dependent on G6PD: no G6PD means no NADPH, no reduction, and methylene blue itself, an oxidant dye, then causes haemolysis. The non-enzymatic routes — ascorbic acid and reduced glutathione — are small and slow, but they are the rationale for ascorbic acid as the alternative antidote in G6PD deficiency and congenital disease.[2]

Why the ferric iron is doubly harmful

Ferric iron cannot bind oxygen, so each methaemoglobin subunit is a lost carrying site — a functional anaemia. Worse, by stabilising the relaxed state of the neighbouring ferrous subunits it shifts the dissociation curve to the left, so the oxygen that is bound is held more tightly and released less readily to the tissues. The patient suffers both a loss of carrying capacity and impaired unloading — the molecular basis of the tissue hypoxia, lactic acidosis and end-organ injury at high levels.[1]

The two monitor paradoxes

The pulse-oximetry paradox. A standard pulse oximeter uses two wavelengths calibrated only for oxy- and deoxyhaemoglobin. Methaemoglobin absorbs strongly at both, so as it rises the saturation is driven toward about 85 percent and becomes insensitive to the true arterial oxygenation — giving the saturation gap. Giving more oxygen does not move the number.[3]

The arterial-blood-gas paradox. A standard blood-gas machine does not measure saturation — it calculates it from PaO2, pH and temperature on the assumption that all haemoglobin is normal, so it reports a normal calculated saturation despite the true saturation being low. Only co-oximetry, with four or more wavelengths that directly measure oxy-, deoxy-, carboxy- and methaemoglobin, reveals the truth. The lung is intact, so PaO2 is normal.[2]

Why methylene blue can fail or harm

[1] [1]

One more trap lives in the drug chart, not the blood. Methylene blue is a weak monoamine-oxidase inhibitor, and the FDA warns it can precipitate serotonin syndrome in a patient on SSRIs, SNRIs, MAOIs, tramadol, linezolid or methadone. Check the serotonergic history before the syringe.[1][5]

The mimics — and the discriminator that ends each

The unifying problem is cyanosis that does not respond to oxygen, and the differential splits into the dyshaemoglobins and everything else. The discriminator is the blood colour and the co-oximetry.[1][6]

[1] [1]

Two distinctions deserve emphasis. Methaemoglobin drives the pulse oximeter toward 85 percent; carboxyhaemoglobin is misread as oxyhaemoglobin so the oximeter reads falsely high near 100 percent — a clean discriminator. Methaemoglobin and sulphaemoglobin are both measured by co-oximetry and produced by the same oxidants, but sulphaemoglobin is irreducible and lasts the red-cell lifespan. Distinguishing acquired from congenital at the bedside: congenital means lifelong cyanosis from infancy, a family history, a methaemoglobin of only 10 to 30 percent with chronic compensation, and no precipitant.[2][5]

The history is the investigation

Build the assessment around the cardinal triad and a hunt for the precipitant. Establish the exposure — prescription drugs (dapsone, sulphonamides, primaquine, phenazopyridine, nitroprusside, nitroglycerin, benzocaine or prilocaine), occupational or recreational exposure (aniline dyes, nitrites or poppers, nitrobenzene, chlorates, naphthalene), recent procedures (endoscopy, bronchoscopy, dental work, intubation, transoesophageal echo with benzocaine), the water source in an infant, and smoke inhalation. Note the timing of onset relative to the exposure, the symptoms, the comorbidity — anaemia, cardiac, respiratory, G6PD status, pregnancy — and a family history for suspected congenital disease.[1]

Three bedside manoeuvres earn marks. Draw blood into a heparinised tube and compare it with a control: methaemoglobin blood is chocolate-brown and does not turn bright red on shaking in air — the filter-paper drop that stays brown is a classic. Apply 100 percent oxygen: the cyanosis of methaemoglobin does not improve, unlike true hypoxaemic cyanosis. Recognise the saturation gap — a pulse oximeter near 85 percent with a normal PaO2 and a normal calculated saturation. In the unstable patient run ABCDE: intubate if the GCS is under 8, give high-flow oxygen, establish IV access, and monitor continuously.[1][3]

[1]

Co-oximetry — the only test that measures it directly

The gold standard is co-oximetry on arterial or venous blood, reporting methaemoglobin as a percentage of total haemoglobin; over 1.5 percent is abnormal. A venous sample is acceptable and avoids arterial puncture. The first-line panel adds a venous or arterial blood gas to confirm the metabolic picture — severe methaemoglobin causes a lactic acidosis with low bicarbonate, while PaO2 stays normal — a full blood count, reticulocytes and film for anaemia and Heinz bodies or bite cells of oxidative haemolysis, a haemolysis screen of LDH, haptoglobin and bilirubin, electrolytes, lactate, glucose, troponin and an ECG for end-organ injury, and a drug or oxidant screen.[2]

Check G6PD ideally before methylene blue, but never delay treatment in a severely symptomatic patient. The caveat is that G6PD levels are falsely elevated during acute haemolysis because the most deficient cells have already lysed — recheck two to three months later. When the picture is congenital — lifelong cyanosis, family history, a methaemoglobin of 10 to 30 percent in an otherwise well patient with no precipitant — send a cytochrome b5 reductase enzyme assay and haemoglobin electrophoresis or globin gene sequencing for haemoglobin M.[1][5]

Some older co-oximeters cannot distinguish sulphaemoglobin from methaemoglobin, very high methaemoglobin can saturate the assay and report falsely low, and frozen or mishandled samples artefactually raise the level. Interpret the percentage against the total haemoglobin: an anaemic patient may be profoundly hypoxic without cyanosis because the absolute methaemoglobin in g/dL is what determines the colour.[3]

Resuscitation — stop the oxidant, give oxygen, then the antidote

[1]

Resuscitation and the first specific measures are simultaneous: stop the oxidant and give oxygen while you prepare the antidote. Secure the airway and intubate if the GCS is under 8 or deterioration is rapid, give high-flow 100 percent oxygen through a non-rebreather mask to maximise the oxygen carried by the remaining functional haemoglobin and the dissolved oxygen, establish IV access, monitor continuously for the arrhythmia of high-level disease, give isotonic crystalloid for hypotension, and check bedside glucose. Stop and remove the oxidant — discontinue dapsone, withhold benzocaine, remove the patient from the chemical source, change the infant's water source. Confirm with co-oximetry and check G6PD where practical, but never delay methylene blue in a severely symptomatic patient.[1][3]

[1] [4]

Methylene blue — the first-line antidote

Know the dose, the mechanism, and the contraindications verbatim. The dose is 1 to 2 mg/kg IV — 0.1 to 0.2 mL/kg of the 1 percent solution, 10 mg/mL — given slowly over 5 minutes, with a response within 30 to 60 minutes as the patient visibly turns pink. Repeat 1 to 2 mg/kg after 30 to 60 minutes if symptoms persist or the level remains high, to a maximum of 7 mg/kg in 24 hours; larger doses are themselves oxidant and cause haemolysis while paradoxically raising the methaemoglobin.[1]

[1] [1]

When the antidote cannot be used — the alternatives

For G6PD deficiency, refractory disease, or contraindication, the ladder steps to four alternatives. Know which to reach for and why.[1]

[1] [1]

Source-specific measures that change the plan

Three precipitants each need a tailored add-on. Dapsone, well water, and smoke inhalation behave differently and the extra step matters.[4]

For dapsone-induced methaemoglobinaemia, the long 20 to 40 hour half-life means the level recurs after each methylene-blue dose — give repeated doses or a continuous infusion, add cimetidine 300 mg orally or IV every 6 hours to inhibit the CYP generation of the hydroxylamine, consider N-acetylcysteine, and monitor the level every 4 to 6 hours for 24 to 48 hours. For infantile well-water nitrate poisoning, change to an alternative water source and do not boil the water — boiling concentrates the nitrate — give methylene blue 1 mg/kg cautiously if symptomatic after checking G6PD, ascorbic acid for mild disease, supportive care, notify public health, and test the well. For smoke inhalation, where carbon monoxide, cyanide and methaemoglobin coexist, treat carbon monoxide with high-flow or hyperbaric oxygen, cyanide with hydroxocobalamin — avoid sodium thiosulphate or nitrite, which themselves generate methaemoglobin — and methaemoglobin with methylene blue, sequencing by the dominant toxin.[1][6]

Disposition follows severity. Severe methaemoglobin over 50 to 60 percent, coma, seizures, severe acidosis, arrhythmia or haemodynamic instability needs ICU, with benzodiazepines for seizures, ACLS for arrhythmia, fluids and vasopressors for shock, and transfusion for anaemia or haemolysis. An asymptomatic patient with a level under 20 to 30 percent and the oxidant stopped is observed with serial levels every 4 to 6 hours and discharged when the level is falling and symptoms have gone. Congenital forms are managed as an outpatient with lifelong oral ascorbic acid 200 to 500 mg a day or riboflavin 20 to 30 mg a day, reassurance that chronic cyanosis is well tolerated, and genetic counselling.[1][5]

The preventable harm — pitfalls that recur

The recurring failures trace to a short list, and most are preventable. Trusting the monitor and missing the saturation gap delays co-oximetry — the cyanosed patient with a reassuring pulse oximetry and a normal calculated saturation is the classic miss. Giving methylene blue without checking G6PD in a susceptible patient causes oxidative haemolysis, the antidote turning into the toxin. Giving methylene blue to a patient on serotonergic drugs precipitates serotonin syndrome.[1]

The dosing pitfalls matter: exceeding 7 mg/kg in 24 hours is itself oxidant and raises the level; using methylene blue for sulphaemoglobinaemia is futile because it is irreducible; and missing the recurrent dapsone case because the cimetidine was forgotten sends the level back up. Finally, treating an anaemic patient on percentage alone misses severe disease — use the absolute methaemoglobin in g/dL when the total haemoglobin is low, and transfuse to raise the functional haemoglobin.[1][4]

Evidence and regional practice

The anchoring references shape modern practice. The Wright 1999 review (Annals of Emergency Medicine) remains the canonical teaching reference for aetiology, pharmacology and management. The Ash-Bernal 2004 series (Medicine) of 138 cases established dapsone and topical or local anaesthetics as the leading drug causes. The Iolascon 2021 recommendations (American Journal of Hematology) give the current diagnostic and treatment framework, including the conservative threshold for mild asymptomatic cases and the G6PD and serotonergic caveats.[1][4][5]

Regionally, UK NPIS and TOXBASE emphasise benzocaine as a leading iatrogenic cause, a conservative threshold for mild asymptomatic cases, and checking G6PD before methylene blue where practical without delaying severe disease. In the United States the FDA issued a boxed warning and in 2018 withdrew over-the-counter benzocaine teething products after severe infant cases, and warns that methylene blue can precipitate serotonin syndrome in patients on SSRIs, SNRIs or MAOIs and is contraindicated in G6PD deficiency. Methylene blue 1 to 2 mg/kg IV remains first-line for symptomatic acquired disease.[1][3]

[1]

Ward-round test — four stems

Stem 1 — slate-grey ten minutes after benzocaine (answer)

A 62-year-old turns slate-grey ten minutes after a benzocaine throat spray for endoscopy. He is breathless and confused; on 100 percent oxygen his saturation stays at 84 percent, the PaO2 is 90 mmHg, and the calculated saturation is 98 percent. What is the diagnosis, the confirmatory test, and the treatment? Model: This is acquired methaemoglobinaemia from benzocaine — the oxygen-refractory cyanosis with a normal PaO2 and a saturation gap is the signature. Confirm with co-oximetry, the only test that measures methaemoglobin directly (a venous sample is acceptable); over 1.5 percent is abnormal. Stop the benzocaine, give high-flow 100 percent oxygen, and give methylene blue 1 to 2 mg/kg IV slowly over 5 minutes, repeating after 30 to 60 minutes to a maximum of 7 mg/kg in 24 hours — the patient visibly turns pink within the hour. Check G6PD where practical before the dose, but do not delay treatment in a severely symptomatic patient, and check the drug chart for serotonergic agents because methylene blue is a weak MAO inhibitor.[1][3]

Stem 2 — cyanosis in a G6PD-deficient patient on dapsone (answer)

A 34-year-old on dapsone for dermatitis herpetiformis becomes cyanosed and dyspnoeic over days; the methaemoglobin is 38 percent and his G6PD assay is low. Why is methylene blue contraindicated, and what do you give instead? Model: Methylene blue depends on the NADPH-methaemoglobin reductase shunt, which needs NADPH from G6PD — in G6PD deficiency there is no NADPH, so the antidote fails, and methylene blue itself is an oxidant dye that then causes oxidative haemolysis. Give high-flow oxygen, stop the dapsone, and treat with ascorbic acid 300 to 1000 mg a day (IV for rapid effect) for slow non-enzymatic reduction, add N-acetylcysteine to support glutathione regeneration and conjugate the hydroxylamine metabolite, and arrange exchange transfusion if the level is over 50 to 60 percent with ongoing symptoms. The dapsone half-life is 20 to 40 hours, so expect recurrence and monitor the level every 4 to 6 hours.[1][4]

Stem 3 — the blue baby on well water (answer)

A four-month-old rural infant fed formula made with well water is slate-grey, lethargic and feeding poorly; the methaemoglobin is 28 percent. What is the cause, and what three things do you do — and what do you not do? Model: This is infantile well-water nitrate methaemoglobinaemia — gut flora reduces nitrate to the more potent nitrite, fetal haemoglobin oxidises readily, and cytochrome b5 reductase activity is only 50 to 60 percent of the adult value. Change to an alternative water source (bottled or municipal) — and do NOT boil the water, because boiling concentrates the nitrate. Give oxygen and supportive care; give methylene blue 1 mg/kg IV cautiously if symptomatic, but check G6PD first because the infant may be deficient. Notify public health and test the well water. Ascorbic acid is an alternative for milder disease.[1][5]

Stem 4 — the smoke-inhalation patient who is cyanosed (answer)

A fire survivor is cyanosed despite high-flow oxygen; co-oximetry shows methaemoglobin 22 percent and carboxyhaemoglobin 28 percent. How do you sequence the treatment, and what cyanide antidote do you avoid? Model: This is combined carbon monoxide, cyanide and methaemoglobinaemia from combustion. Treat carbon monoxide with high-flow 100 percent oxygen, escalating to hyperbaric oxygen for severe poisoning. Treat the methaemoglobin with methylene blue 1 to 2 mg/kg IV given the symptomatic level. For cyanide give hydroxocobalamin — and AVOID sodium thiosulphate or sodium nitrite, because the nitrite generates more methaemoglobin and worsens the picture. Sequence by the dominant toxin, intubate and ventilate early, and monitor all three dyshaemoglobins on co-oximetry.[1][6]

References

1. [1]Wright RO, Lewander WJ, Woolf AD. Methemoglobinemia: etiology, pharmacology, and clinical management Ann Emerg Med, 1999.PMID 10533013
2. [2]Skold A, Cosco DL, Klein R. Methemoglobinemia: pathogenesis, diagnosis, and management South Med J, 2011.PMID 22024786
3. [3]Cortazzo JA, Lichtman AD. Methemoglobinemia: a review and recommendations for management J Cardiothorac Vasc Anesth, 2014.PMID 23953868
4. [4]Ash-Bernal R, Wise R, Wright SM. Acquired methemoglobinemia: a retrospective series of 138 cases at 2 teaching hospitals Medicine (Baltimore), 2004.PMID 15342970
5. [5]Iolascon A, Bianchi P, Andolfo I, Russo R. Recommendations for diagnosis and treatment of methemoglobinemia Am J Hematol, 2021.PMID 34467556
6. [6]Borron SW, Bebarta VS. Asphyxiants Emerg Med Clin North Am, 2015.PMID 25455664